Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Cipla, Glenmark better bets: Rahul Mohindar

      Cipla, Glenmark better bets in pharma space, says Rahul Mohindar, Director, viratechindia.com

    • Bull's Eye: Short Exide, IDFC; buy Shree Renuka, Lanco

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buying opportunity seen in Cipla: Sukhani

      Buying opportunity seen in Cipla, says Sudarshan Sukhani of s2analytics.com.

    • Buy HUL 400 call, says Sukhani

      Buy HUL 400 call, says Sudarshan Sukhani of s2analytics.com.

    • Buy Cipla with stop loss of Rs 320: Sukhani

      Buy Cipla with stop loss of Rs 320, says Sudarshan Sukhani of s2analytics.com.

    • Sun Pharma may slip to Rs 485: Sukhani

      Sun Pharma may slip to Rs 485, says Sudarshan Sukhani, s2analytics.com.

    • Super Six: Top chart picks for today

      On CNBC-TV18's show Super Six, market gurus Manas Jaiswal, Technical Analyst, manasjaiswal.com, Vishal Kshatriya, Sr. Derivative and Technical Analyst, Edelweiss and Rajesh Jain, EVP Reatail Research, Religare Sec place their bets on two stocks each, thus offering investors a variety of options to choose from.

    • Buy Biocon around Rs 320- 321: Gupta

      Buy Biocon around Rs 320- 321, says Amit Gupta of ICICI Direct.

    • Buy Cipla 320 call, says VK Sharma

      Buy Cipla 320 call, says VK Sharma, HDFC Securities.

    • Buy Cipla, Tata Motors, PFC, JP Associates: Indianivesh

      Dharmesh Kant of Indianivesh Securities is positive on Cipla, JP Associates, Tata Motors and PFC.

    • Buy Dr Reddys Labs, Cipla on decline: Sukhani

      Sudarshan Sukhani, technicaltrends.com is of the view that one can buy Dr Reddys Laboratories, Cipla on decline.

    • Bull's Eye: 12 trading ideas for the day

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Buy Cipla, says Sukhani

      Sudarshan Sukhani of technicaltrends.com is of the view that one can buy Cipla.

    • Cipla, Sun Pharma top picks in pharma space: Sukhani

      Cipla and Sun Pharma are top picks in pharma space, says Sudarshan Sukhani of technicaltrends.com.

    • Cipla has target of Rs 318-320: Sukhani

      Cipla has target of Rs 318-320, says Sudarshan Sukhani of technicaltrends.com.

    • Buy Cipla, Divis Labs: Angel Broking

      Shardul Kulkarni of Angle Broking is bullish on Cipla and Divis Labs and bearish on Aban Offshore and Sintex Industries.

    • Buy Cipla, says Rajesh Jain

      Buy Cipla, says Rajesh Jain, EVP Retail Research of Religare Sec.

    • Super Six: Buy or sell call for Oct 14

      On Super Six, a CNBC-TV18 show, market gurus Manas Jaiswal, Technical Analyst of Emkay Global, Rajesh Jain, EVP Retail Research of Religare Sec and Nooresh Mirani, Head, AMSEC-Analyse India place their bets on two stocks each that can potentially make money.

    • Indiabulls Real can slip to Rs 67: Anu Jain

      Indiabulls Real Estate can slip to Rs 67, says Anu Jain, Vice President, IIFL Private Wealth Management.

    • Invest in Cipla, says Jatinder Sharma

      Jatinder Sharma of Equity Strategist advises to invest in Cipla.

    • Exit Cipla on upside: Rajesh Agarwal

      Exit Cipla on upside, says Rajesh Agarwal, Head of Research, Eastern Financiers.

    • Cipla a best stock in pharma space: Bala

      Jai Bala, Chief Market Technician, Cashthechaos.com feels the best setup in the pharmaceutical space is Cipla.

    • Short Cipla, says Prakash Diwan

      Short Cipla, says Prakash Diwan of Asit C Mehta Investment Intermediates.

    • Bull's Eye: 12 trading bets to boost your portfolio

      Bull's Eye, CNBC-TV18's popular game show, where market experts come together to dish out trading strategies for you to make your week more exciting and compete with each other to see whose portfolio is the strongest.

    • Cipla has target of Rs 345: DD Sharma

      Cipla has target of Rs 345, says DD Sharma, Senior Vice President Research, Anand Rathi.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347